Alzheimer & Demantia: Early Alzheimer's disease has a high incidence, but recognition rates are far underestimated!

Mild cognitive impairment (MCI) is an intermediate state between normal aging and dementia, a dementia syndrome
.
Compared with normal older people with age and education, the patient has mild cognitive decline, but daily ability is not significantly affected
.
The core symptom of mild cognitive impairment is cognitive decline, which can involve one or more of memory, executive function, language, use, and visuospatial structural skills, depending on the cause or
site of brain damage.

Recently, scholars from the United States have used available age and race/ethnicity stratification data to develop a stepwise way
to calculate the prevalence of mild cognitive impairment (MCI) and mild AD from clinical syndromes to biomarker-positive.

The results of ≥the method showed that an estimated 9.
2 percent of non-Hispanic whites, 13.
6 percent of non-Hispanic blacks, 11.
1 percent of Hispanic/ethnic groups, and 9.
7 percent of other races/ethnicities among Americans aged 65 years had MCI
.
Among Americans ≥ 65 years of age, the estimated proportion of mild dementia due to AD is 3.
7% among non-Hispanic whites, 7.
0% of non-Hispanic blacks, 5.
3% of Hispanics, and 3.
9%
of other races/ethnicities.
Of these early AD cases, few may be diagnosed, ranging from 13% of circulating non-Hispanic black cases to 27%
of non-Hispanic white cases.

In summary, underrepresentation in clinical trials can be improved by setting recruitment targets that reflect the diversity of the AD patient population and supporting timely diagnosis
.

References:

Estimating prevalence of early Alzheimer's disease in the United States, accounting for racial and ethnic diversity